Thoracic Clinical Trials

With an emphasis on transdisciplinary translational research, the OSUCCC-James facilitates investigator-initiated early phase clinical trials and participates in many cooperative groups.

Protocol No.PITitle
OSU-12117Erin BertinoA Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
OSU-12226Erin BertinoA Phase I Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered with Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects with Select Advanced Solid Tumors
OSU-13087Erin BertinoAn Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-Line Therapy to Patients with Non-Small Cell Lung Cancer
OSU-12012Kristy BrowningDeveloping an ePersonal Health Record (PHR) for delivery of tobacco dependence treatment to oncology patients who smoke
OSU-13204David CarboneIncreasing cures for early stage lung cancer
OSU-13100Bo ChaoA phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib
OSU-13118Bo ChaoDouble blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma
OSU-13035Bo ChaoA Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations
OSU-13230Bo ChaoA Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
OSU-13244Bo ChaoA Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects with Relapsed/Refractory Small Cell Lung Carcinoma
OSU-13275Bo ChaoA Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
OSU-13044Michael EzziePulmonary Rehabilitation in locally advanced Non-Small Cell Lung Cancer
CALGB-30610John GreculaPhase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
OSU-08111John GreculaMR-Predictive-Assay in Pre-Operative Lung Cancer Therapy: Response/Resectability
CALGB-150712John GreculaEmbedded Companion Study to CALGB 30610
CALGB-70702John GreculaEmbedded Companion to CALGB 30610
CALGB-70701Kavitha KosuriEmbedded Companion Study to CALGB-30607
CALGB-60702Kavitha KosuriEmbedded Companion Study to CALGB-30607
CALGB-150707Kavitha KosuriEmbedded Substudy "A Phase II Study of Dasatinib (NSC # 732517) in Patient w/ Previously Treated Malignant Mesothelioma"
OSU-07115Susan Moffatt-BruceImmunobiology of Photodynamic Therapy in Lung Cancer Patients
CALGB-60705Greg OttersonEmbedded Companion Study to CALGB 30704
CALGB-580702Greg OttersonEmbedded Campanion Study to CALGB 30704
CALGB-150701Greg OttersonEmbedded Companion Study to CALGB-30504
CALGB-70809Greg OttersonEmbedded Companion to CALGB-30506: Quality of Life in Patients on CALGB-30506
CALGB-150908Greg OttersonEmbedded Protocol to CALGB-30801
CALGB-60904Greg OttersonEmbedded Companion Studu to CALGB-30801
OSU-12053Greg OttersonA Randomized Phase II Trial of Erlotinib Alone or In Combination with Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
ECOG-E5508Greg OttersonRandomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
CALGB-151108Greg OttersonCORRELATIVE IMAGING ANALYSIS OF CALGB 30406: ERLOTINIB THERAPY IN LUNG CANCER AS A MODEL FOR THE DEVELOPMENT OF BIOLOGICALLY MEANINGFUL RESPONSE METRICS
OSU-12169Greg OttersonPHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A C-MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER
OSU-12184Greg OttersonLung Cancer Mutation Consortium Protocol
OSU-12210Patrick RossRobotic-Assisted Thoracic Surgery (RATS) Patient Registry: PROTOCOL
OSU-12072Patrick RossPhotodynamic Therapy (PDT) Oncology Registry
CALGB-140503Patrick RossA Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small < 2cm Peripheral Non-Small Cell Lung Cancer
OSU-07082Miguel VillalonaAnalysis of FANCD2 Protein Monoubiquitin Status and Nuclear Foci Formation in the Primary Solid Tumors
OSU-09100Miguel VillalonaABT-888 as monotherapy and in combination with Mitomycin C in patients with solid tumors with deficiency in homologous recombination repair.
OSU-12167Miguel VillalonaA Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer
OSU-14039Miguel VillalonaA Prospective Observational Study to Examine, in Routine Clinical Practice in the US, Practice Patterns and Impact on Clinical Decision Making Associated with the FoundationOne Next Generation Sequencing (NGS) Test
RTOG-0937Meng WelliverRANDOMIZED PHASE II STUDY COMPARING PROPHYLACTIC CRANIAL IRRADIATION ALONE TO PROPHYLACTIC CRANIAL IRRADIATION AND CONSOLIDATIVE EXTRA-CRANIAL IRRADIATION FOR EXTENSIVE DISEASE SMALL CELL LUNG CANCER (ED-SCLC)
RTOG-1306Meng WelliverA Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
OSU-08113Jun ZhangRetrospective Evaluation of the Prognostic Value of Total Tumor Volume Versus SUV in Patients with Lung Cancer Undergoing FDG PET/CT

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu